RxDoctor Payments Data

Brady Christensen, DO

Family Medicine · Virginia Beach, VANPI 1780043125

Payments from drug & device makers

$2,514in general payments, 2019–2025

Across 63 payments — averaging $39.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$761
  • Dexcom, Inc.$579
  • Novo Nordisk$389
  • Amgen$273
  • Exact Sciences$203
  • Astellas Pharma US Inc$125
  • plus $183 from 4 others

What the payments were for

  • Food & beverage$2,514100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca17$761
Dexcom, Inc.13$579
Novo Nordisk4$389
Amgen11$273
Exact Sciences9$203
Astellas Pharma US Inc1$125
Abbott4$102
AbbVie2$36
Sobi, Inc1$26
Stryker1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,514 in reported general payments places this provider in the 80th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$57,745
Medicare patients
126
Services billed
617

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide63$67,587
JardianceEmpagliflozin38$43,793
FarxigaDapagliflozin Propanediol40$33,510
EliquisApixaban41$33,488
TrulicityDulaglutide24$27,782
EntrestoSacubitril/Valsartan19$27,479
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$20,761
JanuviaSitagliptin Phosphate12$18,919
Spiriva RespimatTiotropium Bromide12$6,124
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$4,303
Albuterol Sulfate HfaAlbuterol Sulfate78$1,915
Atorvastatin Calcium186$1,501
LantusInsulin Glargine,hum.Rec.Anlog13$1,455
Levothyroxine Sodium121$1,408
Gabapentin88$1,378

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$389$67,58763 claims
AstraZenecaFarxiga, Breztri Aerosphere$761$54,27163 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →